Bio-Rad Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
Bio-Rad Laboratories has a total shareholder equity of $8.7B and total debt of $1.2B, which brings its debt-to-equity ratio to 13.6%. Its total assets and total liabilities are $12.3B and $3.6B respectively. Bio-Rad Laboratories's EBIT is $365.7M making its interest coverage ratio -7.1. It has cash and short-term investments of $1.6B.
Key information
13.6%
Debt to equity ratio
US$1.19b
Debt
Interest coverage ratio | -7.1x |
Cash | US$1.61b |
Equity | US$8.74b |
Total liabilities | US$3.56b |
Total assets | US$12.30b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: BIO.B's short term assets ($3.0B) exceed its short term liabilities ($522.8M).
Long Term Liabilities: BIO.B's short term assets ($3.0B) exceed its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: BIO.B has more cash than its total debt.
Reducing Debt: BIO.B's debt to equity ratio has increased from 10.5% to 13.6% over the past 5 years.
Debt Coverage: BIO.B's debt is well covered by operating cash flow (31.5%).
Interest Coverage: BIO.B earns more interest than it pays, so coverage of interest payments is not a concern.